ストックスクリーナーアプリを入手
7.55
101.33%
3.80
アフターアワーズ：
7.55
前日終値:
$3.75
開ける：
$6.415
24時間の取引高:
201.45M
Relative Volume:
30.33
時価総額：
$582.00M
収益：
-
当期純損益:
$-209.96M
株価収益率:
-2.3892
EPS:
-3.16
ネットキャッシュフロー:
$-176.27M
1週間 パフォーマンス:
+126.39%
1か月 パフォーマンス:
-19.08%
6か月 パフォーマンス:
-44.57%
1年 パフォーマンス:
-25.25%
1日の値動き範囲:
$5.71
$8.07
1週間の範囲:
$3.02
$8.07
52週間の値動き範囲:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
REPL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
7.55 | 291.78M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | ダウングレード | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-23 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-07-22 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-06-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-04-17 | 再開されました | Piper Sandler | Overweight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-17 | 開始されました | BTIG Research | Buy |
| 2020-11-02 | 開始されました | Jefferies | Buy |
| 2020-10-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-09-04 | 開始されました | ROTH Capital | Buy |
| 2019-07-23 | 開始されました | Chardan Capital Markets | Buy |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-25 | 開始されました | Wedbush | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 開始されました | JP Morgan | Overweight |
| 2018-08-14 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Replimune Group Inc (REPL) 最新ニュース
Replimune's Stock Volatility: Navigating Biotech Uncertainty and Immuno-Oncology's Long-Term Promise - AInvest
Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval - Stocktwits
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Replimune stock rises as Cantor Fitzgerald upgrades (REPL) - Seeking Alpha
Replimune Group: Unexpected Surge Analysis - StocksToTrade
Important Notice to Short and Long-Term Shareholders of - GlobeNewswire
REPL Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Fraud Class Action Involving Replimune Group, Inc. - Morningstar
Order flow analysis tools used on Replimune Group Inc.Chart-Based Entry Confirmation for Beginners - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - The Malaysian Reserve
Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - GlobeNewswire Inc.
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma DrugHagens Berman - TradingView
Replimune Faces Investor Lawsuit Over IGNYTE Trial - TipRanks
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on September 22, 2025 - ACCESS Newswire
Replimune Group (REPL.O) Sees Sharp Intraday Surge — But Why? - AInvest
Replimune Faces Market Turbulence: FDA Rejection Leads to Legal Trouble - StocksToTrade
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Morningstar
Combining machine learning predictions for Replimune Group Inc.AI Entry Timing Prediction for Swing Traders - Newser
Market reaction to Replimune Group Inc.’s recent newsFree Stock Market Watch With Alerts - Newser
How to track smart money flows in Replimune Group Inc.Trend Reversal Probability Forecast Update - Newser
Investors in Replimune Group, Inc. (REPL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Replimune’s SWOT analysis: biotech stock faces FDA setback, industry remains positive - Investing.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after - GlobeNewswire
REPL LAWSUIT NOTICE: Replimune Group, Inc. Investors are Notified of the Pending Securities Fraud Class ActionContact BFA Law before the September 22 Deadline - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
Replimune Group, Inc. (REPL) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Important Notice to Long-Term Shareholders of Alto - GlobeNewswire
REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc. - GlobeNewswire
How to escape a deep drawdown in Replimune Group Inc.Free Growth Based Investment Plan Guidance - Newser
Using portfolio simulators with Replimune Group Inc. includedFree Buy Low Sell High Stock Watch - Newser
Order flow analysis tools used on Replimune Group Inc. Buy/Sell Zone Confirmation Technical Analysis - Newser
Securities Litigation in Biotech: Navigating the Replimune Crisis and Its Broader Implications - AInvest
Regulatory Setbacks and Legal Risks: Replimune Group's Turbulent Path in the Biotech Sector - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - WV News
Leerink Partnrs Expects Lower Earnings for Replimune Group - Defense World
REPL CLASS ACTION ALERT: FDA Response Letter Leads to - GlobeNewswire
Replimune Group (NASDAQ:REPL) Cut to “Underperform” at BMO Capital Markets - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Equal Weight” at Barclays - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Neutral” at HC Wainwright - Defense World
REPLIMUNE GROUP, INC. (NASDAQ: REPL) INVESTOR ALERT Investors With Large Losses in Replimune Group, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - ACCESS Newswire
[REPL] ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Replimune Group, Inc. Investors - TradingView
Potential Securities Fraud: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) - ACCESS Newswire
Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Lost Money on Replimune Group, Inc. (REPL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Is Replimune Group Inc. a good long term investmentTremendous wealth creation - PrintWeekIndia
ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Replimune Group Inc (REPL) 財務データ
収益
当期純利益
現金流量
EPS
0.23%
0.40%
大文字化:
|
ボリューム (24 時間):